[Clinical evaluation of latamoxef in the perinatal period].
Latamoxef (LMOX), a new oxacephem antibiotic with high activity against Gram-negative bacteria has been investigated for use in No. of 58 mothers in perinatal period, and obtained following results. Concentration of LMOX in maternal serum was 43.4 micrograms/ml at the 1 hour after intravenous administration of 1 g. In umbilical cord serum and amniotic fluid, LMOX showed good translation after intravenous administration of 1 g into the mother, but no adverse effect appeared in the neonate. LMOX is highly useful antibiotic in perinatal infections, and the safe dose of LMOX to the mother in perinatal period is 1--2 g per day considerably.
D000653:Amniotic Fluid / Q000378:metabolism; D001424:Bacterial Infections / Q000517:prevention & control; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D007263:Infusions, Parenteral; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism; D009070:Moxalactam / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D011247:Pregnancy; D011645:Puerperal Infection / Q000517:prevention & control; D013997:Time Factors
D009070:Moxalactam